| Identification | Back Directory | [Name]
MELAN A | [CAS]
156251-11-5 | [Synonyms]
MELAN A
Mouse melanocytes
MART-1 (27-35), HUMAN
MART-1 (27-35) (huMan)
Melan A
Antigen LB39-AA (27-35) (human)
Antigen SK29-AA (27-35) (human)
Melan-A Protein (27-35) (human)
MART-1 (27-35) (HUMAN) ACETATE SALT
MELONOMA-ASSOCIATED ANTIGEN PEPTIDE
MELANOMA-ASSOCIATED ANTIGEN PEPTIDE
ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL
H-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL-OH ACOH
H-ALA-ALA-GLY-ILE-GLY-ILE-LEU-THR-VAL-OH ACETATE SALT
Melanoma Antigen Recognized By T-Cells 1 (27-35) (human)
MELANOMA-ASSOCIATED ANTIGEN PEPTIDE MART-1 (27-35), HUMAN
Melanoma-associated prostate peptide: MART-1(27-35), human
MART-1 (27-35) (human))|Melanoma-associated antigen peptide: MART-1(27-35),human
L-Alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl-L-valine
L-Valine, L-alanyl-L-alanylglycyl-L-isoleucylglycyl-L-isoleucyl-L-leucyl-L-threonyl- | [Molecular Formula]
C37H67N9O11 | [MDL Number]
MFCD01318802 | [MOL File]
156251-11-5.mol | [Molecular Weight]
813.98 |
| Chemical Properties | Back Directory | [Boiling point ]
1211.9±65.0 °C(Predicted) | [density ]
1.184±0.06 g/cm3(Predicted) | [storage temp. ]
-15°C
| [form ]
lyophilized powder | [pka]
3.32±0.10(Predicted) | [color ]
white | [Water Solubility ]
water, double-distilled: soluble |
| Hazard Information | Back Directory | [Uses]
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL)[1]. | [Biological Activity]
Melanoma-associated antigen recognized by T cells-1 (MART-1) is essential for the functioning of glycoprotein-100 (gp100). Overexpression of the gene has been observed in cutaneous melanoma (CM). In additiondeletion of Mart-1 gene leads to parotid metastatic melanoma. | [References]
[1] Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1;180(1):347-52. DOI:10.1084/jem.180.1.347
[2] Nolte A, et al. Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma[M]//Transplantation in Hematology and Oncology II. Springer, Berlin, Heidelberg, 2003: 37-40. |
|
|